This study was primarily imposed by the ever increasing need for detoxification of asbestos and asbestos containing materials (ACM), with potential application onsite. The present work investigates potential detoxification of pure chrysotile (Chr) asbestos via a combined treatment of oxalic acid dihydrate (Oxac) (Η2C2Ο4·2Η2Ο) with silicates, such as tetraethoxysilane (TEOS) (SiH20C8O4) and pure water glass (WG) (potassium silicate) (K2SiO3). These reagents used in the experimental procedure, do not cause adverse effects on the environment and are cost effective. The results of FTIR, XRD, optical and scanning microscopy coupled with EDS analyses indicated that all of the applied treatments destructed the Chr structure and yielded silica of amorphous phase and the biomaterial glushinskite from the Oxac reacted with brucite [Mg(OH)2] layer. Each of the proposed formulations can be applied for the detoxification of asbestos, according to priorities related to the specific products of the recovery treatment. Therefore, Oxac acid leaching followed by the TEOS addition is preferred in cases of glushinskite recovery; TEOS treatment of asbestos with subsequent Oxac addition produced amorphous silica production; finally Oxac acid leaching followed by WG encapsulated the asbestos fibers and can be used in cases of onsite asbestos and ACM detoxification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhazmat.2015.11.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differentiation of antigen-activated B cells into pro-proliferative germinal center (GC) B cells depends on the activity of the transcription factors MYC and BCL6, and the epigenetic writers DOT1L and EZH2. GCB-like Diffuse Large B Cell Lymphomas (GCB-DLBCLs) arise from GCB cells and closely resemble their cell of origin. Given the dependency of GCB cells on DOT1L and EZH2, we investigated the role of these epigenetic regulators in GCB-DLBCLs and observed that GCB-DLBCLs synergistically depend on the combined activity of DOT1L and EZH2.
View Article and Find Full Text PDFThread-Filler: A Standardized Combination Therapy.
J Craniofac Surg
January 2025
Department of Plastic, Reconstructive, and Aesthetic Surgery, Bilkay Clinic, Izmir, Turkey.
Advanced technology and increasing knowledge about aging faces have combined to create the illusion of thread lifting to replace surgical interventions. However, results that came far beyond expectations led to a heavy suspicion of these tools. However, combined treatments with fillers would have better outcomes with a synergetic effect.
View Article and Find Full Text PDFComparison of Capizzi and High-dose Methotrexate Approaches in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol
January 2025
Division of Hematology and Oncology, Istanbul University Oncology Institute, İstanbul, Turkey.
Childhood cancers, with leukemia at the forefront, comprise 97% acute leukemia and 3% chronic leukemia, with 75% of acute leukemias being of lymphoblastic origin. Over the past 50 years, survival rates have witnessed a remarkable increase, progressing from around 10% to achieving cure rates exceeding 90% in certain childhood ALL subgroups with the advent of combined therapies. Between 1999 and 2018, a total of 123 patients diagnosed with B-ALL were initially identified, but after applying exclusion criteria, 105 patients were included in the evaluation, who were treated with COG protocols at our center.
View Article and Find Full Text PDFSynthesis and Biological Evaluation of a New Biphenyl-Based Organogold(III) Complex with In Vitro and In Vivo Anticancer Activity.
J Med Chem
January 2025
Sorbonne Université, CNRS Institut Parisien de Chimie Moléculaire, IPCM, F-75005 Paris, France.
Despite recent advances in cancer treatment, there is still a need for novel compounds with antineoplastic activity. Among 11 biphenyl-based organogold(III) -heterocyclic carbene (NHC) (BGC) complexes of general formula [(C^C)Au(NHC-pyr)X], where (C^C) = 4,4'-ditertbutylbiphenyl, X = Cl or phenylacetylide, and (NHC-pyr) is a pyridyl-substituted NHC ligand, the complex bearing a 4-CF-pyridyl substituent and a chloride ligand showed promising antineoplastic activity on the triple negative breast cancer cell line. was able to induce cell apoptosis but had no effect on the cell cycle.
View Article and Find Full Text PDFAdvances in Radionuclide-Labeled Biological Carriers for Tumor Imaging and Treatment.
ACS Appl Mater Interfaces
January 2025
Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Biological carriers have emerged as significant tools to deliver radionuclides in nuclear medicine, providing a meaningful perspective for tumor imaging and treatment. Various radionuclide-labeled biological carriers have been developed to meet the needs of biomedical applications. This review introduces the principles of radionuclide-mediated imaging and therapy and the selected criteria of them, as well as a comprehensive description of the characteristics and functions of representative biological carriers including bacteria, cells, viruses, and their biological derivatives, emphasizing the labeled strategies of biological carriers combined with radionuclides.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!